Avant View

AVANT VIEW Quarterly Report Q2 2026

Q2 M&A reinforced the enabling-technology premium, with acquirers paying up for delivery platforms and AI-enabled tooling over the underlying assets themselves. Lilly’s up-to-$7B acquisition of Kelonia reads as a straight cell-therapy buy, but the real asset is the iGPS in vivo delivery platform that collapses ex vivo CAR-T manufacturing into a single injection — delivery, not biology, is the differentiator, and it anchors the most aggressive M&A year in pharma on record (over $25B across 10 deals in 2026). The same logic ran through Roche’s $1.05B acquisition of PathAI, a clear signal that digital pathology has crossed from pilot to priority as AI and digitization become core infrastructure. METiS TechBio’s Hong Kong IPO — raising a reported $310M at a roughly $1.8B valuation on the strength of its AI-native NanoForge lipid-delivery platform — tied that same AI-plus-delivery thesis to continued capital formation out of Asia.

  • Kelonia acquired by Eli Lilly (up to $7B; $3.25B upfront, April) — Reads as a cell-therapy buy; the real value is the iGPS in vivo gene-delivery platform that turns ex vivo CAR-T manufacturing into a one-time injection.
  • PathAI acquired by Roche ($1.05B, May) — AI-driven digital pathology; extends Roche’s diagnostics and drug-development tooling into machine-learning tissue analysis.
  • METiS TechBio’s Hong Kong IPO (~$1.8B valuation, May) — AI-native LNP and nanomaterial delivery platform (NanoForge); a public-market exit tying the AI-plus-delivery thesis to continued Asia capital formation.

Q2 was a story of concentration. Roughly $4.1B in disclosed investment dollars went into the sector even as deal count fell to 132 from 203 the prior quarter — fewer, much larger checks. Isomorphic Labs’ $2.1B Series B alone accounted for roughly half of all disclosed venture dollars; only four other raises cleared $100M, with the rest a long tail of sub-$50M checks. The signal isn’t that more capital showed up, but that it’s consolidating behind a handful of platforms betting AI can become an autonomous engine for discovery. With compute and model architecture commoditizing, the real moat is high-quality, task-relevant biological data — and the platforms pulling ahead are the ones locking up proprietary data, whether through curated datasets, pharma partnerships, or owned experimental capacity. That data-first logic ran through Isomorphic’s raise (building its own “dataverse”), Nabla Bio’s $70M round, and MoleculeMind’s $100M Series A+ out of Beijing. Beyond Isomorphic, cell-therapy manufacturing and delivery platforms took the largest checks, led by Cellares’ $327M Series D and SonoThera’s $125M Series B.

  • Isomorphic Labs’ $2.1B Series B (May) — The quarter’s largest raise globally, and roughly half of all disclosed venture dollars. AI-first drug-design platform out of DeepMind; led by Thrive Capital with Alphabet, GV, CapitalG, MGX, and Temasek.
  • Cellares’ $327M Series D (June) — Automated cell-therapy manufacturing; grew to $327M with a $50M Prime Radiant Partners investment. Funds a European Smart Factory in Leiden and a path to a 2027 IPO.
  • SonoThera’s $125M Series B (June) — Ultrasound-mediated, nonviral gene-delivery platform; led by Vida Ventures with Leaps by Bayer, J&J JJDC, and Vertex Ventures HC.
  • MoleculeMind’s $100M Series A+ (June) — AI-driven protein design out of Beijing; led by Blue Bridge Capital and Pudong Venture Capital. Continued Asia-based capital for AI-native platforms.
  • Nabla Bio’s $70M Series B (May, $429M pre) — Generative AI for de novo antibody and protein design; BluePointe Ventures and Braidwell.

AVANT VIEW

Q2 2026 was defined by concentration and a widening premium on anything that looks like proprietary infrastructure. Roughly $4.1B in disclosed VC dollars went into biomanufacturing, HealthTech, and TechBio, but deal count dropped sharply to 132 from 203, and Isomorphic Labs’ $2.1B Series B alone made up nearly half of it. M&A told the same story from the buy side: Lilly, Roche, and public-market investors in Hong Kong all paid up for delivery platforms and AI-enabled tooling rather than assets alone, capping pharma’s most aggressive M&A year on record (over $25B across 10 deals).

A number of threads stood out this quarter:

First, the enabling layer kept commanding the premium — and it spread into new sectors. Merck’s $11.3B agreement to acquire Bio-Techne extends the same infrastructure-over-asset logic seen in Kelonia and PathAI into life-science tools themselves. The invisible layer of biopharma is becoming visible.

Second, the “special AI” pitch is giving way to a “special data” one. Isomorphic’s data-heavy raise, AWS’s new Biodiscovery platform, and rising regulatory scrutiny of AI-run manufacturing all point the same direction: as compute and model architecture commoditize, owning proprietary biological data — not just a good model — is becoming the real moat.

Third, ex vivo manufacturing kept cracking while delivery platforms got rewarded. J&J’s decision to discontinue $5B of CAR-T programs landed the same quarter Lilly paid up to $7B for Kelonia’s in vivo delivery platform — a live contrast between the cell-therapy approaches struggling and the ones acquirers are willing to pay for.

Fourth, regulators on both sides of the Atlantic started writing the rules for this wave of enabling tech. The FDA’s warning letter on AI use in drug manufacturing and its draft guidance to accelerate gene therapy development both landed this quarter, alongside the EU’s €10B bioeconomy push to keep European biotech from being sold off.

TOP STORIES

The Tools Layer Gets Its Own Premium: Merck’s $11.3B Bio-Techne Buyout

Merck’s $11.3B acquisition of Bio-Techne is Merck KGaA’s largest deal since Sigma-Aldrich and extends the enabling-layer premium seen in Kelonia and PathAI down into life-science reagents and instruments themselves. Paired with an activist investor building a stake in Bio-Rad this same quarter, it’s a strong signal that consolidation in life-science tools is just getting started.

Amazon Wants a Piece of the Data Moat: AWS Launches a Biodiscovery Platform

AWS’s new Biodiscovery platform packages cloud infrastructure specifically for biological data — a direct validation of the quarter’s central thesis that as compute and model architecture commoditize, the scarce resource is proprietary, task-relevant biological data. When a hyperscaler starts building for that specific moat, the “we have special AI” pitch gets even harder to sell on its own.

Ex Vivo’s Cracks Show: J&J Walks Away from $5B in CAR-T Programs

J&J discontinued its CD20 and CD19/CD20 bispecific CAR-T programs in the same quarter Lilly paid up to $7B for Kelonia’s in vivo delivery platform — a live contrast between the ex vivo manufacturing approaches losing favor and the delivery technology acquirers are rewarding instead.

INDUSTRY NEWS

AI, TechBio & Discovery Platforms

Chai Discovery signs a license agreement with Pfizer for AI-designed antibodies, its second major pharma partnership after Eli Lilly

Leica Biosystems, Indica Labs, and Lunit Partner to Build AI-Powered Computational Pathology Algorithms

Grundium Acquires Visiopharm to Create an Integrated Precision-Pathology Platform

Parse Biosciences and bit.bio Announce a Landmark Alliance to Map Transcription-Factor-Driven Cell Identity

Apoha Exits Stealth with $36M for a Biologics-Developability Platform

Chinese Biotechs Turn to AI and Local Know-How as Buyer Costs Rise

Nomic Bio Joins the HESI Global OASIS Consortium to Build an AI-Ready Toxicity Dataset

Abbelight Named a BOOST Grant Laureate by the Paris-Saclay Cancer Cluster

Lukas Utiger joins the Board of Intrepid Labs

Manufacturing, CDMO & Infrastructure

AbbVie to Build a $1.4B Manufacturing Facility in Durham, North Carolina

Sartorius Opens a New Competence Center for Cell and Gene Therapy Components in Freiburg

Lonza Acquires Rapid Microbial-Testing Firm Redberry SAS

CordenPharma Acquires Ambiopharm to Expand Global Peptide API Capacity

Mayo Clinic Renames and Expands Its Regenerative Medicine Center into a Multi-State Biomanufacturing Push

PL BioScience Adds Avant Bio Operating Advisor Maik Jornitz to Its Board of Directors

M&A & Strategic Transactions

Standard BioTools and Treeline Biosciences Agree to a Reverse Merger That Takes Treeline Public

Elliott Management Builds an Activist Stake in Bio-Rad  and Sartorius

J&J Acquires Firefly Bio to Add a Degrader-Antibody Conjugate Platform to Its Oncology Pipeline

Samsung Electronics Invests $175M in Element Biosciences’ Series E

Repligen Expresses Takeover Interest in BioLife, per a Bloomberg Report

clock.bio’s Assets Bought Out of Administration by Co-Founder Mark Kotter

Regulatory & Policy

FDA Warning Letter Flags Risks of Using AI in Drug Manufacturing

EU Launches a €10B Bioeconomy Push to Keep European Biotech Startups from Being Sold Off

White House’s 100% Tariff on Drugmakers Arrives with Carve-Outs That Soften the Blow FDA Releases Draft Guidance to Accelerate Gene Therapy Development